|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Patient #** | **Biopsy Type** | **% Tumor cells PD-L1 +** | **Tumor PD-L1 Intensity** | **Tumor IRS** | **% Immune cells\* PD-L1 +** | **Immune cells\* PD-L1 Intensity** | **Immune cell\* IRS** |
| Patient 01 | PRE | 0 | 0 | 0 | 0 | 0 | 0 |
|  | EDT | 0 | 0 | 0 | 0 | 0 | 0 |
| Patient 02 | PRE | 1 | 1 | 1 | 1 | 1 | 1 |
|  | EDT | 2 | 1 | 2 | 1 | 1 | 1 |
| Patient 03 | PRE | 60 | 3 | 180 | 75 | 2 | 150 |
|  | PROG | 0 | 0 | 0 | 0 | 0 | 0 |
| Patient 04 | PRE | 1 | 1 | 1 | 3 | 1 | 3 |
|  | EDT | 1 | 1 | 1 | 0 | 1 | 0 |
|  | PROG | 0 | 0 | 0 | 0 | 0 | 0 |
| Patient 05 | PRE | 0 | 0 | 0 | 0 | 0 | 0 |
|  | PROG | 3 | 1 | 3 | 0 | 0 | 0 |
| Patient 06 | PRE | 5 | 2 | 10 | 75 | 2 | 150 |
|  | EDT | 0 | 0 | 0 | 0 | 0 | 0 |
| Patient 07 | PRE | 5 | 1 | 5 | 3 | 2 | 6 |
|  | EDT | 0 | 0 | 0 | 0 | 0 | 0 |
| Patient 08 | PRE | 0 | 0 | 0 | 0 | 0 | 0 |
|  | PROG | 1 | 2 | 2 | 1 | 1 | 1 |
| Patient 09 | PRE | 0 | 0 | 0 | 0 | 0 | 0 |
|  | EDT | 5 | 1 | 5 | 20 | 2 | 40 |
|  | PROG | 1 | 1 | 1 | 2 | 1 | 2 |
| Patient 10 | PRE | 15 | 1 | 15 | 75 | 1 | 75 |
|  | EDT | 0 | 0 | 0 | 0 | 0 | 0 |
| Patient 11 | PRE | 8 | 2 | 16 | 50 | 1 | 50 |
|  | PROG | 0 | 0 | 0 | 0 | 1 | 0 |
| Patient 12 | PRE | 10 | 3 | 30 | 15 | 1 | 15 |
|  | EDT | 80 | 1 | 80 | 40 | 2 | 80 |
|  | PROG | 75 | 1 | 75 | 40 | 2 | 80 |
| Patient 13 | PRE | 0 | 0 | 0 | 0 | 0 | 0 |
|  | PROG | 5 | 1 | 5 | 1 | 1 | 1 |
| Patient 14 | PRE | 40 | 2 | 80 | 20 | 1 | 20 |
|  | EDT | 1 | 1 | 1 | 2 | 1 | 2 |
|  | PROG | 0 | 0 | 0 | 1 | 1 | 1 |
| Patient 15 | PRE | 60 | 1 | 60 | 75 | 2 | 150 |
|  | PROG | 1 | 1 | 1 | 0 | 0 | 0 |
| Patient 16 | PRE | 0 | 0 | 0 | 0 | 0 | 0 |
|  | EDT | 0 | 0 | 0 | 0 | 0 | 0 |
|  | PROG | 0 | 0 | 0 | 0 | 0 | 0 |
| Patient 17 | PRE | 0 | 0 | 0 | 0 | 1 | 0 |
|  | EDT | 1 | 2 | 2 | 0 | 1 | 0 |
|  | PROG | 0 | 0 | 0 | 0 | 0 | 0 |
| Patient 18 | PRE | 0 | 0 | 0 | 1 | 1 | 1 |
|  | EDT | 0 | 0 | 0 | 5 | 2 | 10 |
|  | PROG | 10 | 1 | 10 | 10 | 2 | 20 |
| Patient 19 | PRE | 5 | 1 | 5 | 0 | 0 | 0 |
|  | EDT | 1 | 1 | 1 | 0 | 0 | 0 |
| Patient 20 | PRE | 0 | 0 | 0 | 0 | 0 | 0 |
|  | PROG | 1 | 2 | 2 | 1 | 2 | 2 |
| Patient 21 | PRE | 1 | 1 | 1 | 1 | 1 | 1 |
|  | EDT | 0 | 0 | 0 | 0 | 0 | 0 |
| Patient 22 | PRE | 7 | 1 | 7 | 30 | 1 | 30 |
|  | PROG | 1 | 1 | 1 | 50 | 1 | 50 |
| Patient 23 | PRE | 0 | 0 | 0 | 0 | 0 | 0 |
|  | EDT | 0 | 0 | 0 | 0 | 0 | 0 |
|  | PROG | 5 | 1 | 5 | 10 | 2 | 20 |
| Patient 24 | PRE | 0 | 0 | 0 | 0 | 1 | 0 |
|  | PROG | 5 | 2 | 10 | 25 | 1 | 25 |
| Patient 25 | PRE | 1 | 1 | 1 | 5 | 1 | 5 |
|  | PROG | 0 | 0 | 0 | 0 | 0 | 0 |
| Patient 26 | PRE | 30 | 3 | 90 | 80 | 3 | 240 |
|  | EDT | 40 | 3 | 120 | 80 | 2 | 160 |
| Patient 27 | PRE | 0 | 0 | 0 | 0 | 0 | 0 |
|  | EDT | 0 | 0 | 0 | 0 | 0 | 0 |
| Patient 28 | PRE | 0 | 0 | 0 | 0 | 0 | 0 |
|  | EDT | 0 | 0 | 0 | 0 | 0 | 0 |
| Patient 29 | PRE | 1 | 1 | 1 | 1 | 1 | 1 |
|  | EDT | 1 | 1 | 1 | 0 | 0 | 0 |
|  | PROG | 2 | 1 | 2 | 5 | 1 | 5 |
| Patient 30 | PRE | 8 | 3 | 24 | 15 | 2 | 30 |
|  | EDT | 1 | 2 | 2 | 1 | 1 | 1 |
|  | PROG | 0 | 0 | 0 | 0 | 0 | 0 |
| Patient 31 | PRE | 0 | 0 | 0 | 0 | 0 | 0 |
|  | PROG | 0 | 0 | 0 | 0 | 0 | 0 |
| Patient 32 | PRE | 60 | 3 | 180 | 6 | 2 | 12 |
|  | EDT | 90 | 2 | 180 | 75 | 1 | 75 |
|  | PROG | 50 | 2 | 100 | 20 | 1 | 20 |
| Patient 33 | PRE | 15 | 3 | 45 | 40 | 2 | 80 |
|  | EDT | 39 | 3 | 117 | 75 | 2 | 150 |
| Patient 34 | PRE | 0 | 0 | 0 | 0 | 0 | 0 |
|  | EDT | 0 | 0 | 0 | 0 | 0 | 0 |
|  | PROG | 5 | 2 | 10 | 15 | 1 | 15 |
| Patient 35 | PRE | 0 | 0 | 0 | 1 | 1 | 1 |
|  | PROG | 2 | 2 | 4 | 60 | 2 | 120 |
| Patient 36 | PRE | 1 | 1 | 1 | 1 | 1 | 1 |
|  | EDT | 0 | 0 | 0 | 0 | 0 | 0 |
|  | PROG | 1 | 1 | 1 | 1 | 2 | 2 |
| Patient 37 | PRE | 40 | 3 | 120 | 40 | 2 | 80 |
|  | EDT | 80 | 1 | 80 | 5 | 1 | 5 |
| Patient 38 | PRE | 2 | 2 | 4 | 5 | 2 | 10 |
|  | EDT | 5 | 1 | 5 | 4 | 1 | 4 |
| Patient 39 | PRE | 1 | 2 | 2 | 2 | 1 | 2 |
|  | EDT | 3 | 1 | 3 | 2 | 1 | 2 |
| Patient 40 | PRE | 5 | 3 | 15 | 15 | 1 | 15 |
|  | EDT | 0 | 0 | 0 | 0 | 0 | 0 |

**Supplementary Table 2:** The percentage of PD-L1 expressing tumor/immune cells and the intensity of staining in these samples used to derive the immuno-reactive score (IRS) for the 40 patients. \*Immune cells= lymphocytes and macrophages